The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Q1 2025 Management View CEO Emily Leproust highlighted record revenue of $88.7 million for Q1 2025, representing 24% year-over-year growth and 5% sequential growth. The gross margin expanded to 48.3%, ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with ...

Global healthcare private equity (PE) deal value surged to an estimated $115 billion in 2024, marking the second-highest ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...